Taken together, these data emphasize the therapeutic potential of MR targeting in obesity, a view strengthened by the observations that treatment with steroidal MR antagonists (MRAs) decreases obesity‐associated vascular inflammation, oxidative stress, and arterial stiffening (DeMarco et al., 2015). Here, NR3C2 is linked to obesity due to melanocortin 4 receptor deficiency.